Our studies would suggest that targeting downstream effectors of PEDF, such as VEGFR translocation and/or processing or γ-secretase activity may represent a promising therapeutic strategy for the treatment of diabetic vascular complications in the eye and other organs. The gene discussed is SERPINF1; the disease is complication.